Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Boston Scientific

Boston Scientific Stock: Is Wall Street Bullish or Bearish?

Boston Scientific has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

Barchart

Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback

Although a seemingly inopportune acquisition appears to have cost Boston Scientific dearly, the current valuation of BSX stock may be too enticing to pass up.

Barchart

Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific's pending trial results could help to drive sales growth for years to come after lower-than-expected sales forecasts.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

The Highest-Rated Healthcare Stock to Buy Now to Hedge Against Oil Price Shocks

Amid oil-driven volatility, investors lean on resilient sectors, with Boston Scientific Corporation now standing out as a steady defensive healthcare play.

Barchart

Is Boston Scientific Stock Underperforming the Dow?

Boston Scientific’s shares are trailing the broader market, yet analysts remain optimistic, signaling confidence in longer-term recovery potential.

Barchart

Health Care Stocks Have Sagged. Can You Bet on a Recovery?

The flagging health care sector has perked up a bit lately. Is it time to invest?

Kiplinger

Don't Miss Out: Strangle Plays on These 3 Top 25 Unusually Active Options Gems!

There were 1,234 unusually active options on Wednesday. Among the top 25 Vol/OI ratios were three popular stocks: Peloton Interactive, Boston Scientific, and Uber Technologies. There’s an argument for both long and short strangles. Here’s why.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Boston Scientific Stock: Analyst Estimates & Ratings

Though Boston Scientific has lagged behind the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Stocks Boosted by Chip Demand Optimism

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.26%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.60%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. March E-mini S&P futures (ESH26 ) rose +0.24%, and March E-mini Nasdaq futures...

Barchart

Is Boston Scientific Stock Underperforming the Nasdaq?

Boston Scientific has underperformed the Nasdaq over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

5 Core Stocks Every Investor Should Own in 2026 and Beyond

Core stocks generate reliable and growing returns for you and your portfolio. Here are five we like for the long term.

Kiplinger

Do Wall Street Analysts Like Boston Scientific Stock?

As Boston Scientific has outpaced the broader market over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.

Barchart

Targa Resources, Take-Two Interactive, Boston Scientific: Why Experts Rate These Stocks at Strong Buy

Wall Street is highly bullish on these three high-quality stocks.

Kiplinger

Boston Scientific Delivers Robust Q3 Despite Tariff Headwinds: Analyst

On Wednesday, Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion, beating the consensus estimate of $4.97 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

These Analysts Increase Their Forecasts On Boston Scientific After Upbeat Earnings

Boston Scientific Corporation (NYSE:BSX) reported better-than-expected third-quarter results on Wednesday.

Benzinga

Boston Scientific Gains Momentum As Growth Broadens, Goldman Sachs Says

Boston Scientific Corp (NYSE:BSX) delivered "another set of strong top-line results," which trickled down to an earnings beat, according to Goldman Sachs.

Benzinga

Boston Scientific Jumps On Strong Guidance, Heart Devices Fuel Topline Growth

Boston Scientific Corporation (NYSE:BSX) reported third-quarter 2025 revenues of $5.07 billion on Wednesday, beating the consensus estimate of $4.97 billion.

MarketBeat

Beware the Death Cross: 3 Stocks Triggering This Spooky Signal

The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Boston Scientific To Acquire Nalu Medical In $600 Million Pain Relief Deal

Boston Scientific Corp (NYSE:BSX) announced on Friday that it has agreed to acquire Nalu Medical Inc., a privately held maker of minimally invasive devices for chronic pain treatment.

Barchart

What You Need To Know Ahead of Boston Scientific's Earnings Release

Boston Scientific is poised to release its third-quarter results later this month, and analysts project a double-digit earnings growth.

Benzinga

Boston Scientific To Rally More Than 35%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

Top 3 Health Care Stocks That May Explode In September

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Barchart

Is Boston Scientific Stock Outperforming the S&P 500?

As Boston Scientific has outpaced the S&P 500 Index over the past year, analysts are strongly optimistic about the stock’s prospects.

MarketBeat

3 Biotech Catalysts Present Major Opportunity

Three promising biotech names stand out for potentially catalyzing drugs currently on the market or in development; here's why they may rally further.

Benzinga

Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue

The Food and Drug Administration (FDA) said on Wednesday it is monitoring a potential safety issue involving Boston Scientific Corporation’s (NYSE:BSX) ENDOTAK RELIANCE defibrillation leads, following a letter from the company alerting healthcare providers of possible reduced shock efficacy.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.